The effectiveness of immunotherapy in the complex treatment of community-acquired pneumonia of mild course in organized groups

Author:

Tatevosov V. R.1ORCID,Kostinov M. P.2,Protasov A. D.3,Osiptsov V. N.1,Gainitdinova V. V.4,Polishchuk V. B.2,Poddubikov A. V.2

Affiliation:

1. Main Military Clinical Hospital of the National Guard Troops of the Russian Federation

2. I. I. Mechnikov Scientific Research Institute of Vaccines and Serums

3. Samara State Medical University

4. I. M. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

Community-acquired pneumonia is one of the most common acute infectious diseases, especially in organized groups. Community-acquired pneumonia in military personnel is a serious problem of the medical service and is diagnosed 2–3 times more often than among civilians. The purpose of the study. To study the clinical features of the action of “Immunovac-VP-4 ®” in the complex treatment of community-acquired pneumonia in new recruits. Materials and methods. The study group included 88 conscripted military personnel from among the new recruits who were hospitalized with a diagnosis of mild community-acquired pneumonia. The main group of the study included 35 patients receiving basic antibacterial therapy in combination with the therapeutic vaccine “Immunovak-VP-4 ®”. The control group included 53 patients who received only standard basic antibacterial therapy. Results. In the main study group, the frequency of repeated respiratory infections in all nosologies was lower than in the control group, statistically significant differences were noted in relation to pneumonia and acute rhinosinusitis. A decrease in the level of IL-1β in blood serum was revealed after 15 days (p = 0.05) and 6 months after discharge from the hospital (p = 0.002) in the main group compared with the control group. After 15 days, in the group of patients receiving “Immunovak-VP-4 ®”, there was a decrease in IL-6 levels relative to the baseline (p = 0.04) and it became lower than the control group (p = 0.04). Conclusion. The use of the “Immunovak-VP-4 ®” vaccine can be considered as a way to improve the treatment of community-acquired pneumonia: it can be a drug for treatment, prevention of complications, and an instrument in immunorehabilitation. The use of “Immunovak-VP-4 ®” in the complex treatment of community-acquired pneumonia of mild course is accompanied by a decrease in the activity of systemic inflammation: a decrease in serum levels of IL-1β, IL-6.

Publisher

Astrakhan State Medical University

Reference20 articles.

1. Zabolevaemost vzroslogo naseleniya Rossii v 2022 g. = Morbidity of the adult population of Russia in 2022. Moscow: Ministry of Health of the Russian Federation; 2023; 32 p. (In Russ.).

2. Matyukhin A. V., Emel'yanov V. N. Epidemiological and socio-economic assessment of the importance of community-acquired pneumonia in the Armed Forces of the Russian Federation. Izvestiya rossiyskoy voennomeditsinskoy akademii = Proceedings of the Russian Military Medical Academy. 2019; S1-2: 12–14. (In Russ.).

3. Rendon A., Rendon-Ramirez E. J., Rosas-Taraco A. G. Relevant Cytokines in the Management of Community-Acquired Pneumonia. Current Infectious Disease Reports. 2016; 18 (10). doi: 10.1007/s11908-016-0516-y.

4. Ishiguro T., Takayanagi N., Yamaguchi Sh. et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Internal Medicine. 2013; 52 (3): 317–324. doi: 10.2169/internalmedicine.52.8830.

5. Chuchalin A. G., Bilichenko T. N., Zverev V. V. et al. Gosudarstvennoye sanitarno-epidemiologicheskoye normirovaniye Rossiyskoy Federatsii. 3.3.1. Vaktsinoprofilaktika. Immunizatsiya polisakharidnoy polivalentnoy vaktsinoy dlya profilaktiki pnevmokokkovoy infektsii = State sanitary and epidemiological regulation of the Russian Federation. 3.3.1. Vaccination. Immunization with polysaccharide polyvalent vaccine for the prevention of pneumococcal infection. The publication is official. Moscow, 2008. 14 p. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3